Your browser doesn't support javascript.
loading
Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo.
Larivière, Ynke; Garcia-Fogeda, Irene; Zola Matuvanga, Trésor; Isekah Osang'ir, Bernard; Milolo, Solange; Meta, Rachel; Kimbulu, Primo; Robinson, Cynthia; Katwere, Michael; McLean, Chelsea; Hens, Niel; Matangila, Junior; Maketa, Vivi; Mitashi, Patrick; Muhindo-Mavoko, Hypolite; Van Geertruyden, Jean-Pierre; Van Damme, Pierre.
Affiliation
  • Larivière Y; Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk.
  • Garcia-Fogeda I; Global Health Institute, Department of Family Medicine and Population Health, University of Antwerp, Wilrijk.
  • Zola Matuvanga T; Centre for Health Economics Research and Modelling Infectious Diseases, Vaccine and Infectious Diseases Institute, University of Antwerp, Antwerp, Belgium.
  • Isekah Osang'ir B; Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk.
  • Milolo S; Global Health Institute, Department of Family Medicine and Population Health, University of Antwerp, Wilrijk.
  • Meta R; Tropical Medicine Department, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
  • Kimbulu P; Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk.
  • Robinson C; Global Health Institute, Department of Family Medicine and Population Health, University of Antwerp, Wilrijk.
  • Katwere M; Tropical Medicine Department, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
  • McLean C; Tropical Medicine Department, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
  • Hens N; Tropical Medicine Department, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
  • Matangila J; Janssen Vaccines & Prevention, Leiden, the Netherlands.
  • Maketa V; Janssen Vaccines & Prevention, Leiden, the Netherlands.
  • Mitashi P; Janssen Vaccines & Prevention, Leiden, the Netherlands.
  • Muhindo-Mavoko H; Centre for Health Economics Research and Modelling Infectious Diseases, Vaccine and Infectious Diseases Institute, University of Antwerp, Antwerp, Belgium.
  • Van Geertruyden JP; Data Science Institute, Interuniversity Institute for Biostatistics and statistical Bioinformatics, UHasselt, Diepenbeek, Belgium.
  • Van Damme P; Tropical Medicine Department, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
J Infect Dis ; 229(4): 1068-1076, 2024 Apr 12.
Article in En | MEDLINE | ID: mdl-37673423
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Smallpox Vaccine / Hemorrhagic Fever, Ebola / Ebola Vaccines / Ebolavirus Type of study: Clinical_trials Limits: Animals / Humans Country/Region as subject: Africa Language: En Journal: J Infect Dis Year: 2024 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Smallpox Vaccine / Hemorrhagic Fever, Ebola / Ebola Vaccines / Ebolavirus Type of study: Clinical_trials Limits: Animals / Humans Country/Region as subject: Africa Language: En Journal: J Infect Dis Year: 2024 Document type: Article